

## **ASX ANNOUNCEMENT**

31 July 2025

### **Appendix 3Y Correction**

Epsilon Healthcare Limited (ASX: EPN) (“**EPN**” or “**Company**”) releases this announcement to advise of a correction to its Appendix 3Y (Change of Director’s Interest Notice) lodged on 29 July 2025 for one of its directors, Mr Alan Beasley.

The original notice did not disclose Mr Beasley’s existing holding of 10,500,000 ordinary shares prior to the change reported on 25 July 2025. The corrected version now accurately reflects this pre-existing holding, in line with the requirements under ASX Listing Rule 3.19A.2 and section 205G of the Corporations Act 2001.

No other changes have been made to the original Appendix 3Y.

We apologise for the oversight and confirm that the company has reviewed its internal processes to help ensure timely and accurate disclosures going forward.

Please contact us if any further information is required.

**- ENDS -**

This ASX announcement has been authorised for release by the Board of Epsilon Healthcare Limited (ASX: EPN).

For further information contact us via [corporate@epsilonhealthcare.com.au](mailto:corporate@epsilonhealthcare.com.au).

#### **About Epsilon Healthcare**

Epsilon Healthcare Limited (ASX: EPN) is an Australian based, globally active healthcare organisation. With a diversified and vertically integrated portfolio of assets, including healthcare, pharmaceutical contract development and manufacture & pharmacy services, EPN is well placed to capitalise on current and emerging markets. Visit [epsilonhealthcare.com.au](http://epsilonhealthcare.com.au) for more information.

Rule 3.19A.2

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>EPSILON HEALTHCARE LIMITED</b>
<b>ABN</b>	<b>33 614 508 039</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Alan Preston Beasley
<b>Date of last notice</b>	25 September 2023

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
<b>Date of change</b>	25 July 2025
<b>No. of securities held prior to change</b>	Options - Nil Ordinary shares – 10,500,000
<b>Class</b>	Options - unlisted
<b>Number acquired</b>	10,000,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil - unlisted options - expiring 24 June 2028, exercise price \$0.02 or the TERP of any future capital raise between the date of issue of the options and the expiry date
<b>No. of securities held after change</b>	Options - 10,000,000 Ordinary shares – 10,500,000

---

+ See chapter 19 for defined terms.

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options to lenders under DOCI approved at EGM 27 June 2025
---	--

## Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A